Get the Stockscreener App
19.98
5.75%
-1.22
Adma Biologics Inc stock is traded at $19.98, with a volume of 4.13M.
It is down -5.75% in the last 24 hours and up +3.04% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$21.20
Open:
$20.72
24h Volume:
4.13M
Relative Volume:
1.25
Market Cap:
$5.62B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
24.37
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
-15.05%
1M Performance:
+3.04%
6M Performance:
-11.67%
1Y Performance:
+188.31%
1-Day Range:
$19.86
$21.48
1-Week Range:
$18.75
$24.17
52-Week Range:
$7.96
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.98 | 5.62B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - Zacks Investment Research
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - TradingView
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, R - GuruFocus
ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours - marketscreener.com
Earnings call transcript: ADMA Biologics Q1 2025 sees revenue beat, mixed stock reaction - Investing.com
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
ADMA Biologics (ADMA) Misses Revenue Estimates Despite Strong Growth - GuruFocus
ADMA Biologics Announces $500M Share Repurchase Program - TipRanks
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, Revenue of $114.8M Misses Expectations - GuruFocus
Earnings Flash (ADMA) Adma Biologics Posts Q1 Diluted EPS $0.11, vs. FactSet Est of $0.15 - marketscreener.com
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
ADMA Options Activity Suggests Anticipated Post-Earnings Volatility | ADMA Stock News - GuruFocus
Adma Biologics options imply 10.9% move in share price post-earnings - TipRanks
3 Mid-Cap Medical Stocks Outperforming the Market - Investing.com
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - Zacks Investment Research
ADMA Biologics Earnings Preview - Nasdaq
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - Zacks Investment Research
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
(ADMA) Technical Data - news.stocktradersdaily.com
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? - MSN
Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know - MSN
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas - The Globe and Mail
Why ADMA Biologics, Inc. (ADMA) Surged on Monday - MSN
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
ADMA Biologics (ADMA) Achieves Key FDA Approval for Production B - GuruFocus
ADMA Biologics (ADMA) Attracts Hedge Fund Attention Amid Takeover Speculation - GuruFocus
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):